Subscribe to our press releases
Communiqué from extraordinary general meeting in ChromoGenics AB (publ) on 18 December 2019
An extraordinary general meeting in ChromoGenics AB (publ) was held on 18 December 2019 at the company’s premises on Söderforsgatan 1 in Uppsala whereby the shareholders primarily resolved on the following matters.
Resolution on adoption of new articles of association
The extraordinary general meeting resolved to adopt new articles of association regarding the limits for the share capital (§ 4) and the number of shares (§ 5) in accordance with the following.
§ 4 The company’s share capital shall be not less than SEK 35,000,000 and not more than SEK 140,000,000.
§ 5 The number of shares in the company shall be not less than 175,000,000 and not more than 700,000,000.
§ 4 The company’s share capital shall be not less than SEK 80,000,000 and not more than SEK 320,000,000.
§ 5 The number of shares in the company shall be not less than 400,000,000 and not more than 1,600,000,000.
The managing director, or any person appointed by the board of directors, is authorised to make such smaller adjustments to the resolution that may be necessary in connection with registration of the resolution with the Swedish Companies Registration Office and Euroclear Sweden AB.
Resolution on authorisation to the board of directors to resolve on new issues of shares
The extraordinary general meeting of shareholders resolved to authorise the board of directors to, on one or several occasions for the period up to the next annual general meeting, resolve on an increase of the company’s share capital by an issue of new shares. The board of directors is authorised to resolve on an issue of shares with pre-emption rights for existing shareholders and on an issue in kind and/or by way of set off. The authorisation may be used for issues of shares within the limits of the company’s articles of association.
An issue in accordance with the authorisation shall be on market conditions. The board of directors is authorised to decide on the terms and conditions regarding issues under the authorisation. The reason that the board of directors shall be authorised to resolve on an issue in kind and/or by way of set-off is that the company shall be able to carry out new issues of shares to raise capital to the company.
The managing director, or any person appointed by the board of directors, is authorised to make such smaller adjustments to this resolution that may be necessary in connection with registration of the resolution with the Swedish Companies Registration Office and Euroclear Sweden AB.
The resolutions at the extraordinary general meeting were adopted unanimously.
Uppsala on 18 December 2019
ChromoGenics AB (publ)
The board of directors
Jerker Lundgren, CEO
Lars Ericsson, CFO and Head of Communications
Tel: +46 (0)18 430 0430
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
ChromoGenics offers dynamic glass with controllable heat- and light transmission and static glass with world leading performance. The company’s unique technology ConverLight® provides sustainable solar control for increased indoor comfort and energy efficiency. ConverLight also contributes to Green Building certifications. In 2016 the company started commercial sales to real estate projects in Scandinavia.
ChromoGenics is located in Uppsala, Sweden, and the technology is derived from the world leading research center at Ångström Laboratory at Uppsala University. The plant has been partly financed by a conditional loan from the Swedish Energy Agency.
ChromoGenics share (CHRO) is listed on Nasdaq First North Growth Market with Erik Penser Bank as Certified Adviser, e-mail: email@example.com, tel.: +46 (0) 8 463 83 00.